Pfizer Collaborates with Dewpoint to Develop Therapies for Rare Form of Muscular Dystrophy

 Pfizer Collaborates with Dewpoint to Develop Therapies for Rare Form of Muscular Dystrophy

Pfizer Collaborates with Dewpoint to Develop Therapies for Rare Form of Muscular Dystrophy

Shots:

  • Dewpoint to receive up front payment and up to $239M as research, development & commercial milestones along with royalties on sales of the therapies
  • The companies collaborated for the development of therapies to treat DM1
  • The companies will collaborate their expertise to advance the novel therapeutic solutions addressing the patients’ needs

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Business Wire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post